Motivational Support Program in Chronic Low Back Pain After Multidisciplinary Functional Rehabilitation (EMOTIV)

Evaluation of the Effectiveness of a MOTIVational Support Program After Multidisciplinary Functional Rehabilitation in Chronic Low Back Pain

Chronic low back pain (CLBP) is a major public health problem. Multidisciplinary functional rehabilitation program (FRP), which give patients the skills to better manage pain and return to physical activity, are effective in the short term. In the medium and long term, due to lack of motivation, two thirds of patients stop their physical activity again, causing them to fall back into the vicious circle of pain. Investigators hypothesise that a remote assessment and motivational support program (MSP) based on an application, piloted by a care coordinator, could allow the continued improvement of symptoms and activities observed after the FRP programs, and thus limit the consequences of CLBP for the patient and society. The main objective of this study is to evaluate the effect of the motivational support program EMOTIV, on disability and pain at one year, in chronic low back pain patients who have benefited from a FRP program.

Study Overview

• Status: Recruiting
• Conditions: Chronic Low-back Pain
• Intervention / Treatment: Behavioral: Motivational Support Program Emotiv

Detailed Description

Multidisciplinary functional rehabilitation program (FRP) have shown their efficacy in disabilitie patient suffering from Chronic low back pain (CLBP). Unfortunately, at medium and long term two thirds of patients stop their physical activity due to lack of motivation. These patients then fall back into their painful vicious circle. Investigators hypothesis that motivational support program (MSP) based on an application, piloted by a care coordinator could increase the motivation to continue physical activity and thus limit the consequences of CLBP for the patient and society. The main objective is to evaluate the impact of a MSP (EMOTIV) on pain and functional abilities assessed according to the COMI scale (Core Outcome Measure Index), 12 months after a FRP in patients with LPBC. This program is compared to usual care as currently done. The secondary criteria concern: physical, neuropsychological and medico-economical criteria. This is a multicentre, cluster randomized trial. All adult patient suffering from low back pain, having finished a FRP and possessing a smartphone, will be included. Investigators plan to include 150 patients in 6 centres. The duration of the inclusion period is 12 months; The duration of participation of each subject is 24 months. Inclusion will be on the last day of the FRP program. The Follow-up in consultation is scheduled at 3, 12 and 24 months with evaluation of usual criteria (physical, self-questionnaires, and advice on the practice of physical activities depending on what is achieved). In Pitie salpetriere center only, patients will have in addition: lumbar MRI at 3 and 12 months; central pain awareness assessment. The activity of patients in the MSP group will be recorded continuously par EMOTIV App; pain, mental health and days off every week and self-questionnaires at 1, 2 and 6 months. The primary analysis of all endpoints will be performed in the intent-to-treat population, i.e. all patients randomized to the study. The COMI score will be compared between the 2 randomized groups by a linear mixed model.

• Study Type: Interventional
• Enrollment (Estimated): 150
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Violaine FOLTZ, Dr; Phone Number: 01 42 17 79 58; Email: violaine.foltz@aphp.fr
• Study Contact Backup: Name: Bruno FAUTREL, Pr; Phone Number: 01 42 17 78 01; Email: bruno.fautrel@aphp.fr

Study Locations

• France
  • Paris, France, 75013
    • Recruiting
    • Hopital Pitie Salpetriere
    • Contact: Violaine FOLTZ, Dr; Phone Number: 01 42 17 79 58; Email: violaine.foltz@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• age 18 or over
• Disabling chronic low back pain: chronic painful patient, that is to say suffering from pain for more than 3 months, having interrupted all physical activity because of low back pain and have an indication for a FRP for low back pain.
• Having reached the end of an FRP program
• Possession of a smartphone
• Fluency in French (writing, reading)
• Health insurance coverage (beneficiary or beneficiary) except State Medical Aid.
• Patient Informed Consent Signature

Exclusion Criteria:

• Pregnant woman
• Patient refusal
• Patient deprived of liberty and patient under legal protection measure (guardianship, guardianship)
• Patient participating to another interventional search

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Standard arm; The patients will have the usual care
Experimental: Motivational Support Program Emotiv; The patients will have the motivational support program	Behavioral: Motivational Support Program Emotiv; A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in disability and pain between the experimental (SHP) and control (usual care) groups, measured with the Core Outcome Measure Index (COMI) scale at 12 months.	The Core Outcome Measure Index (COMI) was developed from requirements of international back pain experts. According to European experts, the COMI should currently be recommended in assessment of chronic low back pain. This questionnaire assesses pain and disability in low back pain. It includes 9 items and its score is between 0 and 10. Higher scores is the worse outcome.	12 months after completion of the multidisciplinary functional rehabilitation program

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evolution of pain	Pain will be measured by a Visual Analogic Scale (VAS) with a question about lumbar pain over the last 7 days. Minimum and maximum values are 0 and 100.	At 3 months, 12 months and 24 months
Evolution of flexibility	Flexibility will be evaluated by measuring the hand-to-ground distance	At 3 months, 12 months and 24 months
Evolution of muscular endurance	Muscular endurance will be assessed by measuring Shirado (abdominal endurance). Its score is between 0 and no limit. 0 is the worse outcome.	At 3 months, 12 months and 24 months
Evolution of muscular endurance	Muscular endurance will be assessed by measuring Sorensen (spinal extensor endurance). Its score is between 0 and no limit. 0 is the worse outcome.	At 3 months, 12 months and 24 months
Evolution of disability and pain	Disability and pain will be assessed by the Core Outcome Measure Index (COMI) questionnaire. Its score is between 0 and 10. Higher scores is the worse outcome.	At 3 months, 12 months and 24 months
Evolution of endurance and sports performance (VO2 max)	Endurance and sports performance will be assessed on the treadmill	At 3 months, 12 months and 24 months
Evolution of the intensity of physical activity	Intensity of physical activity will be assessed by the IPAQ (International Physical Activity Questionnaire). Scoring a high level of physical activity on the IPAQ means the physical activity levels equate to approximately one hour of activity per day or more at least a moderate intensity activity level.	At 3 months, 12 months and 24 months
Evolution of muscular trophicity in the 2 groups	Muscular trophicity will be done by the measurement of the cross-sectional area (CSA) of the extensor muscles at the level of the upper and lower plateaus of L4 at the lumbar spine	At 3 months and 12 months
Evolution of the level of anxiety and depression	Level of anxiety and depression will be assessed by the HAD (Hospital Anxiety and Depression) scale. 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus allowing two scores (maximum and worse of each score equal 21)	At 3 months, 12 months and 24 months
Evolution of the level of central pain awareness	Two parameters will be used, in accordance with international recommendations on Quantitative Sensory Testings : the pain pressure threshold using an algometer, at a distance from the painful area (forearm), and the temporal summation by repeating a painful stimulus with a calibrated needle (PinPrick)	At inclusion, 3 months, 12 months and 24 months
Medico-economic analysis	The elements for the medico-economic analysis will be collected on the basis of a questionnaire validated in French. The data collected are : - consultations in general medicine and rheumatology as part of the usual follow-up of patients, - biological or imaging examinations carried out for the spinal problem, - medicinal treatments (drugs, infiltrative procedures) and non-medicinal treatments (physiotherapy, others) carried out for the spinal problem, - any hospitalizations related to the spinal problem	At 3 months, 12 months and 24 months
Cost of care (i.e, health resource use and related costs or direct costs)	Health resource use will be quantified by the number of consultations, biologic and imaging workups, hospitalisations with their motives, and the list of treatments taken by the patients. It will be valued on the basis of the tariffs of the National Health Insurance Fund (CNAM). Health resource use related costs will be expressed in Euros	At 3 months, 12 months and 24 months
Cost of care (i.e, health resource use and related costs or direct costs)	Health resource use will be quantified by the number of consultations, biologic and imaging workups, hospitalisations with their motives, and the list of treatments taken by the patients. It will be valued using data from the Common Classification of Medical Acts (CCAM). Health resource use related costs will be expressed in Euros	At 3 months, 12 months and 24 months
Cost of care (i.e, health resource use and related costs or direct costs)	Health resource use will be quantified by the number of consultations, biologic and imaging workups, hospitalisations with their motives, and the list of treatments taken by the patients. It will be valued using data from the Nomenclature of Medical Biology Acts (NABM). Health resource use related costs will be expressed in Euros	At 3 months, 12 months and 24 months
Cost of care (i.e, health resource use and related costs or direct costs)	Health resource use will be quantified by the number of consultations, biologic and imaging workups, hospitalisations with their motives, and the list of treatments taken by the patients. It will be valued using data from the national scale of costs (ENC) for hospitalisations. Health resource use related costs will be expressed in Euros	At 3 months, 12 months and 24 months
Sick leave days	The number of working days off work will be elicited	At 3 months, 12 months and 24 months
Productivity loss (i.e, sick leave-related costs or indirect costs)	Sick leave days will be valued on the basis of the average daily salaries published each year by the French National Institute of Statistics (INSEE, www.insee.fr). It will be expressed in Euros.	At 3 months, 12 months and 24 months
Satisfaction with the program	Satisfaction with the program will be measured by a Visual Analogic Scale (VAS). Minimum and maximum values are 0 and 100. The better score is 100.	At 3 months, 12 months and 24 months
Adherence to the program	Adherence to the program will be evaluated on the number of connection (minimum value 0 and no maximum)	At 3 months, 12 months and 24 months
Adherence to the program	Adherence to the program will be evaluated on the time of connection (minimum value 0 and no maximum)	At 3 months, 12 months and 24 months
Adherence to the program	Adherence to the program will be evaluated on number of reminders necessary by the coordinator in case of non connection and/or non attendance at the follow-up (minimum value 0 and non maximum)	At 3 months, 12 months and 24 months

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Violaine FOLTZ, Dr, Hôpital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Actual): September 26, 2023
• Primary Completion (Estimated): September 26, 2025
• Study Completion (Estimated): September 26, 2026

Study Registration Dates

• First Submitted: January 23, 2023
• First Submitted That Met QC Criteria: March 20, 2023
• First Posted (Actual): March 22, 2023

Study Record Updates

• Last Update Posted (Actual): August 22, 2025
• Last Update Submitted That Met QC Criteria: August 21, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: Chronic Low-back Pain; Multidisciplinary function rehabilitation; Motivational Support Program Emotiv
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Back Pain; Low Back Pain
• Other Study ID Numbers: APHP210077; 2022-A00828-35 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
• IPD Sharing Time Frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
• IPD Sharing Access Criteria: Researchers who provide a methodologically sound proposal.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No